BRPI0909731A2 - derivados de carbazol inibidores de hsp90, composições que os contêm e a respectiva utilização - Google Patents

derivados de carbazol inibidores de hsp90, composições que os contêm e a respectiva utilização

Info

Publication number
BRPI0909731A2
BRPI0909731A2 BRPI0909731-7A BRPI0909731A BRPI0909731A2 BR PI0909731 A2 BRPI0909731 A2 BR PI0909731A2 BR PI0909731 A BRPI0909731 A BR PI0909731A BR PI0909731 A2 BRPI0909731 A2 BR PI0909731A2
Authority
BR
Brazil
Prior art keywords
alkyl
compositions containing
hsp90 inhibitor
carbazole derivatives
formula
Prior art date
Application number
BRPI0909731-7A
Other languages
English (en)
Inventor
Alasia Marcel
Bertin Luc
Certal Victor
Halley Frank
Mailliet Patrick
Minoux Hervé
Ruxer Jean-Marie
Mendez-Perez Maria
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39930567&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0909731(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Publication of BRPI0909731A2 publication Critical patent/BRPI0909731A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

"derivados de carbazol inibidores de hsp90, composições que os contêm e a respectiva utilização". a presente invenção refere-se aos novos produtos de fórmula (i): nos quais het representa um heterociclo eventualmente substituído por um ou vários radicais r1 ou r'1,r é escolhido no grupo constituído pela fórmula (ii) com r1 e/ou r'1, escolhidos dentre h, halogênio, cf3, nitro, ciano, alquila, hidróxi, mercapto, amino, alquil amino, dialquil amino, alcóxi, fenil alcóxi, alquil tio, carbóxi livre ou esterificado por um radical alquilam carbo- xamida,co-nh(alquil), con(alquil)2, nh-co-alquil, sulfonaimida, nh-s02- alquil, s(0)2-nhalquil, s(02)-n-(alquil)2, todos esses radicais substituído s; w1, w2, w3 representam independentemente ch ou n; x representa o á- tomo de o, s, nr2, c(0), s(0), ou s(0)2; z representa h, hal.-o-r2 ou-nh- r2 com r2 representa h, alquila, ciclo alquila ou hetero ciclo alquila eventu-almente substituídos; esses produtos estando sob todas as formas isômeras e os sais, a título de medicamentos.
BRPI0909731-7A 2008-03-14 2009-03-13 derivados de carbazol inibidores de hsp90, composições que os contêm e a respectiva utilização BRPI0909731A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0801394A FR2928645A1 (fr) 2008-03-14 2008-03-14 Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation
FR0801394 2008-03-14
PCT/FR2009/000267 WO2009122034A2 (fr) 2008-03-14 2009-03-13 Nouveaux derives de carbazole inhibiteurs d'ηsp90, compositions les contenant et utilisation

Publications (1)

Publication Number Publication Date
BRPI0909731A2 true BRPI0909731A2 (pt) 2019-03-06

Family

ID=39930567

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0909731-7A BRPI0909731A2 (pt) 2008-03-14 2009-03-13 derivados de carbazol inibidores de hsp90, composições que os contêm e a respectiva utilização

Country Status (24)

Country Link
US (1) US8309721B2 (pt)
EP (1) EP2265598A2 (pt)
JP (1) JP5674483B2 (pt)
KR (1) KR20100130603A (pt)
CN (1) CN102026992A (pt)
AR (1) AR070836A1 (pt)
AU (1) AU2009232121A1 (pt)
BR (1) BRPI0909731A2 (pt)
CA (1) CA2718488A1 (pt)
CL (1) CL2009000619A1 (pt)
CO (1) CO6251295A2 (pt)
CR (1) CR11653A (pt)
DO (1) DOP2010000272A (pt)
EA (1) EA201071078A1 (pt)
EC (1) ECSP10010473A (pt)
FR (1) FR2928645A1 (pt)
IL (1) IL208059A0 (pt)
MA (1) MA32206B1 (pt)
MX (1) MX2010010018A (pt)
NI (1) NI201000150A (pt)
PE (1) PE20091673A1 (pt)
TW (1) TW200938541A (pt)
UY (1) UY31711A (pt)
WO (1) WO2009122034A2 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011035416A1 (en) * 2009-09-25 2011-03-31 Aegera Therapeutics Inc. Hsp90 modulating compounds, compositions, methods and uses
CN103313970B (zh) * 2011-01-07 2016-09-07 大鹏药品工业株式会社 新型二环式化合物或其盐
BR112013017416A2 (pt) 2011-01-07 2019-09-24 Taiho Pharmaceutical Co Ltd derivado de indola ou indazola ou sal do mesmo
JP5842630B2 (ja) 2011-03-16 2016-01-13 株式会社リコー カルバゾール誘導体、及び半導体ナノ結晶
JP2014075556A (ja) * 2012-10-05 2014-04-24 Idemitsu Kosan Co Ltd 有機エレクトロルミネッセンス素子用材料、及びそれを用いた有機エレクトロルミネッセンス素子
WO2014108168A1 (en) * 2013-01-10 2014-07-17 Merck Patent Gmbh Piperidinylcarbazole as antimalarial
EP3059225A4 (en) 2013-10-17 2017-09-06 Shionogi & Co., Ltd. Novel alkylene derivative
MX2016007111A (es) 2013-12-05 2016-08-11 Pharmacyclics Llc Inhibidores de tirosina quinasa de bruton.
US20170158636A1 (en) * 2014-07-16 2017-06-08 Novogen Ltd. Functionalised and substituted carbazoles as anti-cancer agents
ES2711117T3 (es) * 2014-10-01 2019-04-30 Janssen Pharmaceuticals Inc Indoles mono o disustituidos como inhibidores de la replicación del virus del dengue
JOP20150335B1 (ar) * 2015-01-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
BR112017022987A2 (pt) * 2015-04-29 2018-07-24 Arena Pharm Inc 1-heteroaril-indolina-4-carboxamidas como moduladores de gpr52 úteis para o tratamento ou prevenção de distúrbios relacionados com os mesmos
JOP20160086B1 (ar) * 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) * 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) * 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
DE102016122122B4 (de) * 2015-11-18 2021-02-11 Cynora Gmbh Organische Moleküle, insbesondere zur Verwendung in organischen optoelektronischen Vorrichtungen
US9966542B2 (en) * 2016-06-02 2018-05-08 E I Du Pont De Nemours And Company Electroactive materials
DE102017008073A1 (de) * 2017-08-28 2019-02-28 Henkel Ag & Co. Kgaa Neue anionische Tenside und Wasch- und Reinigungsmittel, welche diese enthalten
CN111217741B (zh) * 2019-03-01 2022-03-15 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） 氟取代单咔唑类衍生物、其制备方法及应用
CN117159570B (zh) * 2023-11-01 2024-01-23 云南中医药大学 6-酰氧基甘露糖叠氮乙苷衍生物与氟康唑联合在制备抗耐药白念珠菌药物中的应用
CN117486782A (zh) * 2023-12-29 2024-02-02 中国医学科学院药用植物研究所 一种n-取代咔唑衍生物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1317926B1 (it) * 2000-11-03 2003-07-15 Sigma Tau Ind Farmaceuti Derivati triciclici dell'indolo ad attivita' antiangiogenica.
RS52642B (en) * 2004-11-18 2013-06-28 Synta Pharmaceuticals Corp. TRIAZOLE COMPOUNDS MODULATING HSP90 ACTIVITY
MX2008003202A (es) * 2005-09-16 2008-03-25 Serenex Inc Derivados de carbazol.
US8405508B2 (en) * 2006-08-09 2013-03-26 Emd Millipore Corporation Use of gamma hardened RFID tags in pharmaceutical devices

Also Published As

Publication number Publication date
MA32206B1 (fr) 2011-04-01
FR2928645A1 (fr) 2009-09-18
KR20100130603A (ko) 2010-12-13
UY31711A (es) 2009-11-10
TW200938541A (en) 2009-09-16
US8309721B2 (en) 2012-11-13
WO2009122034A8 (fr) 2010-08-19
CN102026992A (zh) 2011-04-20
US20110166169A1 (en) 2011-07-07
PE20091673A1 (es) 2009-11-14
EA201071078A1 (ru) 2011-04-29
AR070836A1 (es) 2010-05-05
AU2009232121A1 (en) 2009-10-08
CO6251295A2 (es) 2011-02-21
IL208059A0 (en) 2010-12-30
NI201000150A (es) 2011-03-29
CA2718488A1 (fr) 2009-10-08
WO2009122034A3 (fr) 2009-12-03
ECSP10010473A (es) 2010-10-30
EP2265598A2 (fr) 2010-12-29
DOP2010000272A (es) 2010-10-15
JP2011513473A (ja) 2011-04-28
CR11653A (es) 2010-11-22
JP5674483B2 (ja) 2015-02-25
MX2010010018A (es) 2010-12-15
CL2009000619A1 (es) 2011-02-18
WO2009122034A2 (fr) 2009-10-08

Similar Documents

Publication Publication Date Title
BRPI0909731A2 (pt) derivados de carbazol inibidores de hsp90, composições que os contêm e a respectiva utilização
CY1118386T1 (el) Παρασιτοκτονες συνθεσεις
AR078163A1 (es) Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes
CY1119101T1 (el) Ναφθαλινο-ισοξαζολινες ως παραγοντες καταπολεμισης ασπονδυλων παρασιτων
BRPI0810929B8 (pt) uso de um composto de fórmula 1
BR112013009935B8 (pt) Compostos
AR077849A2 (es) Compuestos y composiciones como inhibidores de proteina quinasa
ES2422383T3 (es) Activadores de urea glucoquinasa
AR057023A1 (es) Compuestos heterociclicos con propiedades inhibidoras de hiv-integrasa
AR052866A1 (es) Fenil-metanonas monociclicas sustituidas
BRPI0411721A (pt) derivados de tiazolilpiperidina como inibidores de mtp
CO6160235A2 (es) Isoxazolinas insecticidas
DOP2006000045A (es) Derivados del (1,5-difenil-1h-pirazol-3-il oxadiazol, su preparacion y su aplicacion en terapeutica
UY30499A1 (es) Derivados de amina utiles como agentes anticancerigenos
AR072166A1 (es) Derivado de piperidina y su uso como inhibidor de renina superior
AR063643A1 (es) Compuestos quimicos derivados de quinolina, un metodo de preparacion y composiciones farmaceuticas
DK1981874T3 (da) Aminophenylderivater som nye inhibitorer af histondeacetylase
CR11483A (es) Inhibidores de peptido desformilasa
AR044629A1 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos.
DE602005008953D1 (de) Substituierte chinolinderivate als inhibitoren von mitotischem kinesin
ATE480239T1 (de) Angiogeneseinhibitoren
EA201000101A1 (ru) Производные пиримидина 934
EA200700758A1 (ru) Новые производные бис-азаиндолов, их получение и фармацевтическое применение в качестве ингибиторов киназ
MX2011009806A (es) Nuevos derivados de indazol inhibidores de hsp90, composiciones que los contienen y su uso.
ATE457314T1 (de) Antibiotische spiroderivate

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A, 8A, 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2514 DE 12-03-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]